Completed PHASE3 INTERVENTIONAL NCT00403910

Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study

Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure

Sponsor: Heart Care Foundation

Interventions Canrenone

Updated 7 times since 2017 Last updated: Feb 2, 2021 Started: Sep 30, 2002 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00403910, this PHASE3 trial focuses on Heart Failure and remains completed. Sponsored by Heart Care Foundation, it has been updated 7 times since 2002, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Study Description(click to expand)

The protocol is sponsored by and independent organization and partially supported by Therabel

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heart Care Foundation

Data source: Heart Care Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Avellino, Italy , Aversa (CE), Italy , Barletta (BA), Italy , Bergamo, Italy , Bologna, Italy , Bolzano, Italy , Cagliari, Italy , Caserta, Italy , Cefalù (PA), Italy and 31 more locations